Life Science Leader - Home Page
WEBVolastra Therapeutics is a drug discovery and development leader in the emerging field of chromosomal instability, a phenomenon that can determine how certain solid tumor cancer cells replicate and grow. OSE Immunotherapeutics is poised to begin a confirmatory and pivotal Phase 3 trial for a novel cancer vaccine targeting the second line in ...
FSP Or Full-Service Outsourcing For Clinical Trials? - Life Science …
WEBDec 3, 2013 — Functional service provider (FSP) partnerships have been gaining traction in recent years because of their potential to increase efficiency and flexibility in outsourcing without compromising quality. Well-defined services within the scope of a clinical trial project or program (e.g. data management, biostatistics, or medical writing) are good ...
Pharmaceutical Scientists' Salaries in 2023
WEBJan 15, 2024 — In fact, salaries were up among industry scientists as well as academic scientists (AAPS members) – mean annual base salary from principle, full-time employment in the U.S. as of June 1 (the date of the survey cut off) was $190,100, a 6.7% increase from 2022 ($178,100). Pharmaceutical scientists outside of the U.S. had average base salaries ...
Google Life Sciences Leader Talks AI Opportunities And 'Watch …
WEBAug 29, 2024 — Google’s global market leader for life sciences, Shweta Maniar, spoke with Life Science Leader about how large and small biopharmaceutical companies are using AI to lower costs and expedite timelines. Maniar, who currently sits on several industry boards and has previously worked as a scientific researcher, and as a commercial partnering and strategy principal at Genentech, described Google ...
Life Sciences Industry On Uptick In Virginia
WEBMay 1, 2019 — The numbers of biopharmaceutical companies and medical device and equipment companies increased by 37 and 31 percent respectively during 2014 to 2016. “The life sciences industry is on the uptick in Virginia,” says Gallagher. Most Virginia bioscience companies are locally grown, created by the state’s entrepreneurs or …
Companies To Watch: Volastra Therapeutics - Life Science Leader
WEBJun 26, 2024 — By Ben Comer, Chief Editor, Life Science Leader. Charles Hugh-Jones. Developing biomarkers and therapies targeting chromosomal instability, a hallmark of cancer cell replication. Snapshot. New York City-based Volastra Therapeutics – whose founders and scientific advisors are leading chromosomal instability researchers and experts – have in four years’ time advanced two drug candidates ...
A Systems Approach To Parkinson's Disease - Life Science Leader
WEBAug 30, 2024 — By Ben Comer, Chief Editor, Life Science Leader. Alex Martinez. In August 2023, Gut, a journal published by BMJ, released a study of over 24,000 patients with Parkinson’s disease, finding that certain gastrointestinal disorders — such as difficulty swallowing, constipation, and irritable bowel syndrome (IBS) — might specifically predict Parkinson’s disease.
Valuing A Life Sciences Company
WEBOct 1, 2009 — For example, $1 million received five years in the future would be worth only $402,000 today, using a discount rate of, say, 20% per annum. At a discount rate of 30% per annum, the present value of $1 million would be $269,000. Obviously, the discount rate selected has a marked effect on the outcome of the analysis.
Companies To Watch: Aurion Biotech - Life Science Leader
WEBAug 30, 2024 — By Ben Comer, Chief Editor, Life Science Leader. Greg Kunst. Developing an allogeneic cell therapy for eye diseases at scale for the masses . Snapshot. Privately-held Aurion Biotech is developing an allogeneic combination cell therapy — neltependocel, which is allogeneic human corneal endothelial cells, combined with Y-27632, an inhibitor of Rho-associated, coiled-coil containing protein ...
How Serial Entrepreneur Robert Hariri Is Revolutionizing Cell …
WEBAug 1, 2019 — Advice From A Successful Serial Entrepreneur. Robert Hariri, M.D., Ph.D., a successful serial entrepreneur and CEO of Celularity, believes a lot of companies fail because they have a very linear development strategy. And if they reach a milestone and fail, there isn’t much of a future. “A lot of scientists have a discovery — a molecule, a ...